At a glance
- Calcitonin (salmon) is an FDA-approved drug, marketed as Miacalcin (first approval: July 3, 1986).
- PubMed lists 1,817 publications mentioning it, including 177 randomized controlled trials and 721 animal-only studies.
- ClinicalTrials.gov lists 154 registered studies testing it (26 active).
- FDA's adverse event system (FAERS) holds 2,380 reports mentioning it; 1,775 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA017808 | MIACALCIN | Approved, marketed | July 3, 1986 | MYLAN IRELAND LTD |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Salmon calcitonin prescribing for acute phantom limb pain after amputation.
- Amylin Receptor Signalling in the Laterodorsal Tegmental Nucleus Controls Food Intake Through Projections to the Ventral Tegmental Area.
- Engineering small peptide secretion in Komagataella phaffii.
- Transient Osteoporosis of Bilateral Knee Joints in Twin Pregnancy: A Case Report - A Valuable Addition to the Medical Literature.
- On-demand peptide therapeutics for multi-year space exploration: analysis of clinical and operational relevance and recombinant production feasibility.
- Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation.
- Impact of hydrophobic ion pair type and self-nanoemulsifying drug delivery systems composition on the oral delivery of salmon calcitonin.
- Parathyroid adenoma causing hypercalcemic crisis masquerading as acute abdomen in a 7-year-old: a case report.
- Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials.
- Evaluation of the efficacy of salmon calcitonin nasal spray on bone healing following surgical removal of impacted third molar: a randomized controlled study.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 154
- Active
- 26
- With posted results
- 28
Conditions studied
Show 40 more studies
All 154 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 2,380
- Serious
- 1,775
- With death outcome
- 214
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.